337 related articles for article (PubMed ID: 37697370)
1. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
2. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
3. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
4. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
5. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Xu L; Ma X; Zhang X; Zhang C; Zhang Y; Gong S; Wu N; Zhang P; Feng X; Guo J; Zhao M; Ren Z; Zhang P
Mol Cancer; 2023 Dec; 22(1):195. PubMed ID: 38044421
[TBL] [Abstract][Full Text] [Related]
6. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Thakur PC; Miller-Ocuin JL; Nguyen K; Matsuda R; Singhi AD; Zeh HJ; Bahary N
J Transl Med; 2018 Jul; 16(1):190. PubMed ID: 29986726
[TBL] [Abstract][Full Text] [Related]
8. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Wu L; Ge Y; Yuan Y; Li H; Sun H; Xu C; Wang Y; Zhao T; Wang X; Liu J; Gao S; Chang A; Hao J; Huang C
Cancer Lett; 2022 Nov; 548():215864. PubMed ID: 35981571
[TBL] [Abstract][Full Text] [Related]
10. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
12. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Pan CH; Otsuka Y; Sridharan B; Woo M; Leiton CV; Babu S; Torrente Gonçalves M; Kawalerski RR; K Bai JD; Chang DK; Biankin AV; Scampavia L; Spicer T; Escobar-Hoyos LF; Shroyer KR
Mol Oncol; 2020 Aug; 14(8):1800-1816. PubMed ID: 32533886
[TBL] [Abstract][Full Text] [Related]
13. BZW1 Facilitates Glycolysis and Promotes Tumor Growth in Pancreatic Ductal Adenocarcinoma Through Potentiating eIF2α Phosphorylation.
Li Z; Ge Y; Dong J; Wang H; Zhao T; Wang X; Liu J; Gao S; Shi L; Yang S; Huang C; Hao J
Gastroenterology; 2022 Apr; 162(4):1256-1271.e14. PubMed ID: 34951995
[TBL] [Abstract][Full Text] [Related]
14. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract][Full Text] [Related]
15. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
16. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.
Hu C; Xia R; Zhang X; Li T; Ye Y; Li G; He R; Li Z; Lin Q; Zheng S; Chen R
Mol Cancer; 2022 Jan; 21(1):24. PubMed ID: 35045883
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Wang L; Zhang Y; Wang W; Zhu Y; Chen Y; Tian B
PLoS One; 2017; 12(8):e0184110. PubMed ID: 28854261
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
[TBL] [Abstract][Full Text] [Related]
19. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
20. YTHDC1-mediated augmentation of miR-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect.
Hou Y; Zhang Q; Pang W; Hou L; Liang Y; Han X; Luo X; Wang P; Zhang X; Li L; Meng X
Cell Death Differ; 2021 Nov; 28(11):3105-3124. PubMed ID: 34021267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
